Screener
Dyne Therapeutics, Inc. DYN Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(120,854) | $(115,361) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 13,081 | 13,020 |
| Depreciation and amortization expense | 550 | 502 |
| Non-cash lease expense | 116 | 75 |
| Non-cash interest expense | 79 | — |
| Accretion of premium on marketable securities | (271) | (616) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dyne Therapeutics, Inc.'s stock-based comp?
- Dyne Therapeutics, Inc. (DYN) reported stock-based comp of $13.08M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Dyne Therapeutics, Inc.'s stock-based comp increased by 0.5% year-over-year, from $13.02M to $13.08M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s stock-based comp has grown at a 27.2% compound annual growth rate (CAGR), from $17.54M to $45.85M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Dyne Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude